aXichem (AXIC) Q3 2025 earnings summary

Executive summary

• Net sales for Jan–Sep 2025 reached 14,603 TSEK, up from 7,179 TSEK year-over-year, with Q3 sales at 4,568 TSEK versus 504 TSEK last year.

• Operating loss for Jan–Sep was -12,304 TSEK, compared to -10,963 TSEK last year; Q3 operating loss improved to -3,030 TSEK from -5,545 TSEK.

• After-tax result for Jan–Sep was -12,360 TSEK, a slight improvement from -12,501 TSEK year-over-year.

• Strong demand for aXiviteⓇ and first major commercial order for aXiphenⓇ in Brazil marked key milestones.

Financial highlights

• Cash and cash equivalents at Sep 30, 2025, were 3,081 TSEK, down from 8,613 TSEK last year.

• Equity ratio at period end was 86%, compared to 89% last year.

• Investments in intangible, tangible, and financial assets totaled 4,164 TSEK for Jan–Sep, up from 3,735 TSEK.

• Depreciation for Jan–Sep was 3,611 TSEK, up from 3,140 TSEK.

• Earnings per share for Jan–Sep were -0.21 SEK, improved from -0.37 SEK last year.

Outlook and guidance

• Anticipates continued growth in orders for both animal feed and dietary supplements in coming years.

• Expects increasing sales of aXiviteⓇ in the US and EU, especially in gut health, sports, and weight control.

• Ongoing regulatory processes in the EU and Brazil for phenylcapsaicin as a feed additive; fast-track registration in Brazil for dairy cows underway.